The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Tonix Pharmaceuticals Holding Corp shares valued at $86,200 were purchased by LEDERMAN SETH on May 15 ’25. At $21.55 per share, LEDERMAN SETH acquired 4,000 shares. The insider’s holdings grew to 4,005 shares worth approximately $92515.5 following the completion of this transaction.
As published in their initiating research note from Noble Capital Markets on April 18, 2022, Tonix Pharmaceuticals Holding Corp [TNXP] has been an Outperform. Analysts at ROTH Capital upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid April. As of August 18, 2017, ROTH Capital has increased its “Neutral” rating to a “Buy” for TNXP. Earlier on September 07, 2016, ROTH Capital downgraded its rating. Their new recommendation was “a Neutral” for TNXP stock which previously was a “a Buy”.
Analyzing TNXP Stock Performance
During the last five days, there has been a surge of approximately 21.96%. Over the course of the year, Tonix Pharmaceuticals Holding Corp shares have dropped approximately -29.96%. Shares of the company reached a 52-week high of $58.30 on 01/28/25 and a 52-week low of $6.76 on 03/04/25. A 50-day SMA is recorded $18.40, while a 200-day SMA reached $22.18.
Support And Resistance Levels for Tonix Pharmaceuticals Holding Corp (TNXP)
According to the 24-hour chart, there is a support level at 21.62, which, if violated, would cause prices to drop to 20.15. In the upper region, resistance lies at 23.98. The next price resistance is at 24.87. RSI (Relative Strength Index) is 67.40 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.47, which suggests the price will increase in the coming days. Percent R is at 4.31%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
